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Virtual screeningSumoylation is a reversible post-translational modiﬁcation that involves the covalent attachment of small
ubiquitin-like modiﬁer (SUMO) proteins to their substrate proteins. Prior to their conjugation, SUMO proteins
need to be proteolytically processed from its precursor form to mature or active form. SUMO speciﬁc proteases
(SENPs) are cysteine proteases that cleave the pro or inactive form of SUMO at C-terminus using its hydrolase
activity to expose two glycine residues. SENPs also catalyze the de-conjugation of SUMO proteins using their
isopeptidase activity, which is crucial for recycling of SUMO from substrate proteins. SENPs are important for
maintaining the balance between sumoylated and unsumoylated proteins required for normal cellular physiolo-
gy. Several studies reported the overexpression of SENPs in disease conditions and highlighted their role in the
development of various diseases, especially cancer. In this review, we will address the current biological under-
standing of various SENP isoforms and their role in the pathogenesis of different cancers and other diseases. We
will then discuss the advances in the development of protein-based, peptidyl and small molecule inhibitors of
various SENP isoforms. Finally, we will summarize successful examples of computational screening that allowed
the identiﬁcation of SENP inhibitors with therapeutic potential.
© 2015 Kumar and Zhang. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
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Sumoylation is a reversible process that involves the post-
translational modiﬁcation of target proteins with an approximately
10 kDa small ubiquitin-like modiﬁer (SUMO) protein. Sumoylation is
an important mechanism regulating the activities of various proteins in-
volved in cellular processes likeDNA replication and repair, chromosome81 45 503 9559.
er B.V. on behalf of the ResearchNetw
0/).packing and dynamics, genome integrity, nuclear transport, signal trans-
duction and cell proliferation [1–5]. In sumoylation SUMO proteins are
covalently attached to the ε-amino group of lysine residues in speciﬁc
target proteins via an enzymatic cascade that requires a sequential action
of an activating enzyme E1, a conjugating enzyme E2 and a ligase E3
[1–5] (Fig. 1A). The ﬁrst step in the sumoylation pathway involves the
conjugation of a SUMO protein to SUMO activating enzyme 1 (SUMO
E1) that starts with the binding of ATP. The SUMO E1 subsequently
catalyzes the adenylation of SUMO C-terminus at the expense of ATP to
form SUMO-AMP intermediate. Following the formation of SUMO-AMP
intermediate, the catalytic residue Cys173 on SUMO E1 and SUMO-ork of Computational and Structural Biotechnology. This is an open access article under the
Fig. 1. Sumoylation and desumoylation pathway. (A) In sumoylation, SUMO protein is covalently attached to lysine residues in target proteins via a sequential action of an activating
enzyme E1, a conjugating enzyme E2, and a ligase E3. (B) SENPs possess endopeptidase activity to carry out proteolytic processing at theprecursor SUMOC-terminus (SUMO-2C-terminus
is shown here) to expose two glycine residues. SENPs also possess isopeptidase activity to release conjugated SUMO from substrate proteins.
205A. Kumar, K.Y.J. Zhang / Computational and Structural Biotechnology Journal 13 (2015) 204–211AMP intermediate came close as the result of a large conformational
change in SUMO E1 [6] which is followed by the transfer of SUMO to
the catalytic residue Cys173 on SUMO E1 by the formation of a thioester
bond between SUMO C-terminus and Cys173 [6–8]. The next step
involves the subsequent transfer of SUMO protein from SUMO E1 to
SUMO E2 (also known as Ubc9); again with the formation of a thioester
linkage between the C-terminal glycine in SUMO protein and the
catalytic Cys93 in SUMO E2. Ubc9 is the only known SUMO E2 enzyme,
and its deletion abolishes SUMO conjugation [9–11]. In the last step,
Ubc9 catalyzes the covalent attachment of the SUMO protein to the
ε-amino group in a speciﬁc lysine residue of substrate proteins. SUMO
E3 ligase increases the efﬁciency of this step by associating with both
the substrate protein and Ubc9 [12–14].2. SENP and SENP isoforms
Mammalian cells express four SUMO isoforms: SUMO-1, SUMO-2,
SUMO-3 and SUMO-4. The mammalian SUMO-2 and SUMO-3 are
much more similar to each other than to SUMO-1. SUMO-4 on the
other hand is highly homologous with SUMO-2 and SUMO-3, but its ex-
pression is limited only to a few tissues and organs, mainly the kidney,
lymph and spleen [15,16]. SUMO proteins are expressed as precursors
and need to be proteolytically processed from its pro or inactive form
to mature form [4,17–21]. Sentrin/SUMO-speciﬁc proteases (SENPs)
cleave inactive or pro form of SUMO at the C-terminus via its hydrolase
activity to expose two glycine residues and thereby generating active or
mature SUMO (Fig. 1B) [4,17–21]. In addition to C-terminal proteolytic
206 A. Kumar, K.Y.J. Zhang / Computational and Structural Biotechnology Journal 13 (2015) 204–211processing, SENPs also possess isopeptidase activity that is essential for
the recycling of SUMO proteins [4,17–21]. These enzymes speciﬁcally
cleave the isopeptide bond between the C-terminal glycine of SUMO
and the substrate protein lysine thereby releasing the SUMO protein
from its substrate (Fig. 1B).
Six SENP isoforms (SENP1, SENP2, SENP3, SENP5, SENP6 and SENP7)
have been identiﬁed in mammals. These six SENPs can be divided into
three sub-families based on their sequence homology, substrate speci-
ﬁcity and subcellular localization as shown in Table 1 [4,17–21].
SENP1 and SENP2 constitute the ﬁrst family and have broad speciﬁcity
for SUMO-1/2/3. SENP3 and SENP5 form the second family, while the
third family has SENP6 and SENP7 as its members. Apart from SENP1
and SENP2, all other SENP isoforms prefer SUMO-2/3 over SUMO-1 for
deconjugation. The posttranslational modiﬁcation of substrate proteins
by SUMO-4 has not been observed due to SENP's inability to proteolyt-
ically process SUMO-4 precursor in vivo [16,22]. The maturation of pre-
cursor SUMO-4 seems to be inhibited by the presence of Pro90 residue
in place of Gln in SUMO-1–3. Pro90 causes conformational constraint
and makes the peptide bond to be cleaved inaccessible to the narrow
active site of SENP [22,23]. A P50Q single amino acid mutation made
the precursor SUMO-4 amenable to SENP2processingwhile another ad-
ditional mutation G63Dmade it a highly efﬁcient SENP2 substrate [24].
As for their distribution, SENP1, SENP6 and SENP7 are localized in the
nucleoplasm while SENP3 and SENP5 are conﬁned to the nucleolus.
Although SENP2 is compartmentalized in the nuclear pore complex,
however, along with SENP1 it possesses nuclear export signal to
facilitate its shuttling in and out of the nucleus. While all six isoforms
possess isopeptidase activity, only SENP1, SENP2 and SENP5 can carry
out proteolytic processing of precursor SUMOs.
The N-terminal regions of all six SENP isoforms are more or less
unrelated while a conserved cysteine protease catalytic domain was
observed at the C-terminus [21]. The catalytic cysteineprotease domain,
which is the most studied region, is approximately 250 amino acid res-
idues long and controls the speciﬁcity and function of SENP isoforms.
The N-terminal region is poorly conserved and thought to regulate the
localization of SENP isoforms [21]. The three-dimensional (3D) structur-
al information is available only for the catalytic domains of SENP1,
SENP2 and SENP7 (Table 1). The crystal structures are either in apo
form or in complex with SUMO proteins and a substrate RanGAP1.
The catalytic domain crystal structures of SENP1, SENP2 and SENP7
are very similar [25–30]. The catalytic site is comprised of the typical
catalytic triad (Cys-His-Asp) (Cys603, His533 and Asp550 for SENP1;
Cys-548, His-478, and Asp-495 for SENP2; His-794, Cys-926 and
Asp-873 for SENP7) analogous to other cysteine proteases. The catalytic
triad is very important for precursor processing and deconjugation ac-
tivities of SENPs and mutation of the catalytic triad residues abolishesTable 1
Biological properties and structural information of SENP isoforms.
SENP isoform Speciﬁcity Subcellular localization Enzymatic activity
SENP1 SUMO-1/2/3 Nucleoplasm Precursor processing, isopeptida
SENP2 SUMO-1/2/3 Nuclear pore Precursor processing, isopeptida
SENP3 SUMO-2/3 Nucleolus Isopeptidase
SENP5 SUMO-2/3 Nucleolus Precursor processing, isopeptida
SENP6 SUMO-2/3 Nucleoplasm Isopeptidase
SENP7 SUMO-2/3 Nucleoplasm Isopeptidasethe functional activity [26]. SUMO proteins enter the catalytic site via
a narrow tunnel lined by Trp residues, which are essential for the accu-
rate positioning of Gly–Gly motif and sessile bond. It has been revealed
that the sessile bond is oriented in a cis-conﬁguration that creates a kink
in SUMO precursor tails and isopeptide linkage of sumoylated substrate
proteins. These types of cis-peptide bonds are not stable and promote
cleavage [25].
3. Role of SENPs in the development of various diseases
SENP enzymes play a critical role in maintaining normal cellular
physiology by preserving the balance between sumoylated and
unsumoylated proteins. Knockout studies in mice have shown that the
absence of SENP1 or SENP2 is embryonically lethal [31,32]. However
in diseased states, this balance between SUMO modiﬁed and non-
modiﬁed proteins is disrupted due to the altered expression of SENPs.
Several studies implicated the role of various SENP isoforms in the de-
velopment of various diseases, including prostate cancer [31,33–35],
thyroid cancer [36], colon cancer [37], pancreatic cancer [38], athero-
sclerosis [39] and heart diseases [40]. Especially, numerous studies indi-
cated the role of SENPs in prostate cancer development. Androgen
receptor (AR) is the most important protein in the development and
progression of prostate cancer. SENP1 and SENP2 are involved in the
desumoylation of AR and studies have shown that the overexpression
of SENP1 increases AR transcriptional activity [41,42]. In prostate can-
cer, hypoxia-inducible factor 1α (HIF-1α) plays a critical role in regulat-
ing the expression of various genes required for enhanced oxygen
availability in hypoxic tissue environments [43,44]. The sumoylation
of HIF-1α has been reported to have varied outcomes by several groups
[31,45–47]. Polycomb chromobox 4 (CBX4) and RWD-containing
sumoylation enhancer (RSUME) increased the HIF-1α sumoylation by
promoting the transcriptional activity of HIF-1α during hypoxia
[47,48]. Moreover, it is proposed that the stability and/or transcriptional
activity of HIF-1α have been modulated via different sumoylation pat-
terns by CBX4 and the protein inhibitor of activated STAT protein
gamma (PIASγ) [48]. Further, it has been shown that SENP1 is essential
for HIF-1α stability and consequently the regulation of hypoxic
response [31]. Moreover, the absence of SENP1 resulted in active
sumoylation of HIF-1α and ubiquitin dependent degradation [31]. In
another study, Bawa-Khalfe et al. [33] demonstrated the high correla-
tion between HIF-1α and SENP1 expression, indicating SENP1's role in
prostate carcinogenesis. Furthermore, the overexpression of SENP1
has been observed in more than half of the studied samples of prostate
cancer and prostatic intraepithelial neoplasia lesions [33,35]. Analyzing
more than 150 specimens of prostate cancer, Wang et al. also demon-
strated the correlation between SENP1 expression and prostate cancerAmino acid residues Structural information
se 643
Catalytic domain (419–643)
Apo (2IYC, 2XPH, 2XRE, 2CKG)
With SUMO-1 (2IY1, 2G4D)
With SUMO-2 (2IYD, 2CKH)
With SUMO-1 and substrate RanGAP1 (2IY0)
se 589
Catalytic domain (365–589)
Apo (1TH0)
With SUMO-1 (1TGZ)
With preSUMO-2 (2IO0, 3ZO5)
With preSUMO-3 (2IO1)
With SUMO-1 and substrate RanGAP1 (2IO2)
With SUMO-2 and substrate RanGAP1 (2IO3)
574
Catalytic domain (353–574)
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Catalytic domain (567–755)
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1112
Catalytic domain (637–1112)
Not available
984
Catalytic domain (662–984)
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SENP1 in prostate cancer tumorigenesis include the increase in andro-
gen receptor activity [42] and c-Jun dependent transcription [50].
Xu et al. [37] demonstrated the regulation of in vivo and in vitro growth
of colon cancer cells by SENP1. They reported that SENP1 overexpressed
in most of the colon cancer tissues and its silencing arrested the cell
growth in nude mice and the colony formation in a colon cancer cell
line DLD-1.Ma et al. [38] described the overexpression of SENP1 in pan-
creatic ductal adenocarcinoma in comparison with normal tissue. They
further showed that knockdown of SENP1 using siRNA inhibited the
growth of pancreatic ductal adenocarcinoma.
Although SENP1 is the most studied isoform, the role of other SENP
isoforms in pathogenesis has also been reported. SENP2 associates
with MDM2 and regulates its sumoylation levels, which is important
for its binding with tumor suppressor p53 [51,52]. On the other
hand, SENP2 regulates the stability of β-catenin via a WW domain-
containing oxidoreductase (WWOX) and thereby regulates the growth
of hepatocellular carcinoma cells [53,54]. SENP2 also contributes to the
atherosclerotic plaque formation by regulating the levels of p53 and
extracellular signal-regulated kinase-5 (ERK5) under disturbed ﬂow
conditions [39]. Furthermore, the overexpression of SENP2 is also asso-
ciated with congenital heart defects and cardiac dysfunction in murine
hearts [40]. Other SENPs, especially SENP3 and SENP5, are also thera-
peutically relevant, as their elevated expression levels have been
observed in prostate, ovarian, lung, colon, oral squamous cell carcino-
mas and osteosarcoma [55–58]. SENP3 is involved in increasing the
transcriptional activity of HIF-1α through the desumoylation of a co-
regulator p300 [59]. In another study utilizing gene expression datasets
from 1363 patients, Cashman et al. [60] demonstrated the correlation
between low expression of SENP5 and breast cancer patient survival.
4. Identiﬁcation of SENP inhibitors
Since SENPs play a critical role in the development of various dis-
eases including cancer, atherosclerosis and heart diseases, designing
and developing novel inhibitors are of paramount importance. Hence,
there is a growing interest among researchers to discover selective in-
hibitors of SENP isoforms. Several groups focused on the development
of inhibitors of various SENPs useful as chemical tools for studying1
JCP-666 (3)
VEA-499 (5)
7
Fig. 2. A few representative protein-based, peptibiological roles of sumoylation and desumoylation as well as for
exploring the therapeutic potential of SENPs.
One of the earliest SENP inhibitor development strategies made use
of the full or truncated form of SUMO carrying an electrophilic trap or
“warhead” at the C-terminal glycine. In one study, an intein-based
method was employed to equip SUMO-1 and other ubiquitin like pro-
teins with a vinyl sulfone (VS) as an electrophilic trap [61]. These
protein-based probes reacted covalently with SENP2 (1 in Fig. 2) and
other activating, conjugating and deconjugating enzymes through
Michael addition of the catalytic cysteine thiol group with VS moiety.
Pre-incubation of SENP2 with n-ethylmaleimide (NEM), an alkylating
agent, prevented the formation of SUMO-1-VS-SENP2 conjugate and
conﬁrmed that cysteine is required for catalysis [61]. A similar strategy
was used by Borodovsky et al. [62] to synthesize several peptides with
various portions of the C-terminus of ubiquitin-like modiﬁers Nedd8,
SUMO1, FAT10, Fau, and APG12 equipped with a VS electrophilic trap.
A dose-dependent labeling of at least one cell lysate protein by
SUMO1-peptide-VS was shown in this study. Dobrota et al. [63] also re-
ported the synthesis of a peptidyl active site probe (2 in Fig. 2) for SENP1
and SENP2 using a similar approach. This compound contains an
electrophilic trap glycine ﬂuoromethylketone at the C-terminus of a
seven-residue SENP speciﬁc peptide (FQQQTGG). In 2011, Ponder
et al. [64] reported a small molecule inhibitor (JCP-666, 3 in Fig. 2) of
Plasmodium falciparum SENP1 (PfSENP1) by screening a focused library
of cysteine protease inhibitors. JCP-666 harbors a reactive aza-epoxide
linked to a non-natural peptide backbone and displayed an IC50 of
17.9 μM for PfSENP1. A more stable synthetic analog (VEA-260, 4 in
Fig. 2) without the aspartic acid side-chain on the aza-epoxide scaffold
showed similar potency against PfSENP1 (16.2 μM). It is interesting to
note that both compounds also exhibited excellent potency against
human SENP1 and SENP2 [64]. Compound 3 displayed IC50 of 9.0 and
4.7 μM for human SENP1 and SENP2 respectively, while compound 4
showed slightly better activity of 7.1 and 3.7 μM respectively for
human SENP1 and SENP2. Using compound 4 as the starting point,
Albrow et al. [65] synthesized 16 compounds. The inhibitory potency
of these compounds was evaluated against human SENP1, 2, 5, 6 and
7. However, all the synthesized compounds were either less or
equipotent as the parent compound. Moreover, these aza-epoxide
based active site probes demonstrated high background labeling whenBiotin(O)-Teg-FQQQT
2
VEA-260 (4)
6
GN6958 (8)
dyl and small molecule inhibitors of SENPs.
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the same report, Albrow et al. [65] synthesized another series (11 com-
pounds) of human SENP inhibitors based on the compound 4 scaffold
and natural SUMO/ubiquitin amino acid sequence accommodating the
acyloxymethyl ketone (AOMK) reactive group. Bioactivity evaluations
and subsequent IC50 determination ofmore potent compounds revealed
that VEA-499 (5 in Fig. 2)was themost potent inhibitorwith IC50 values
of 3.6 and 0.25 μM for human SENP1 and SENP2 respectively [65].
Furthermore, AOMK based inhibitors were also good active site probes
as they exhibited highly speciﬁc binding in complex proteomes.
In light of the poor pharmacokinetic properties of peptidyl
inhibitors, Qiao et al. [66] designed and synthesized a series of benzodi-
azepine based SENP1 inhibitors. SENP1 activity was evaluated using
SUMO-CHOP reporter ﬂuorescence assay [67]. Two most potent
compounds (compounds 6 and 7 in Fig. 2) displayed IC50 of 15.5 and
9.2 μM. Compounds 6 and 7 also inhibited cancer cell growth in vitro
with IC50 values of 13.0 and 35.7 μM respectively. In another attempt
to develop SENP1 inhibitors as potential anti-cancer agents, Uno et al.
[68] designed and synthesized 1-[4-(N-benzylamino)phenyl]-3-
phenylurea derivatives based on a potent HIF-1α inhibitor. The most
potent compound (GN6958, 8 in Fig. 2) displayed selective SENP1 inhi-
bition with an IC50 of 29.6 μM. Like the parent compound, compound 8
also suppressed HIF-1α without affecting tubulin expression [68]. An-
other study reported the down-regulation of SENP1 expression at
both mRNA and protein levels by the natural product triptolide and
thereby enhancing sumoylation in prostate cancer cells [69]. However,
the actual mechanism of SENP1 downregulation is not known. Recently
utilizing virtual screening approach, several groups reported inhibitors
of various SENP isoforms. These include 2-(4-chlorophenyl)-2-oxoethyl
4-benzamidobenzoate analogs [70], non-covalent SENP inhibitors con-
taining a sulfonyl-benzene group [71], 1,2,5-oxadiazoles [72] and a
cell permeable SENP speciﬁc inhibitor [73]. The identiﬁcation andTable 2
Overview of SENP inhibitors identiﬁed using virtual screening.
SENP target Structure of representative
compounds
Activity of most
potent compounds
Virtual
SENP1 Compound 9
IC50 = 2.38 μM
Compound 10
IC50 = 1.08 μM
Molecu
SENP1, SENP2, SENP7 Compound 11
SENP1 IC50 = 5.9 μM
SENP2 IC50 = 2.9 μM
SENP7 IC50 = 3.5 μM
Compound 12
SENP1 IC50 = 2.1 μM
SENP2 IC50 = 2.0 μM
SENP2 IC50 = 2.7 μM
Molecu
SENP1, SENP2 Compound 13
SENP1 IC50 = 9.7 μM
SENP2 IC50 = 5.9 μM
Compound 14
SENP1 IC50 = N30 μM
SENP2 IC50 = 3.7 μM
Hierarc
and ele
Molecu
SENP1 Compound 15
IC50 = 1.29 μM
Molecu
Autodobiological properties of these inhibitors are summarized in Table 2 and
described in detail below.
5. Computational approaches in the identiﬁcationof SENP inhibitors
In the last two decades, computational approaches have played a
noteworthy role in the identiﬁcation and optimization of small
molecule inhibitors of proteins of therapeutic interests [74,75]. Taking
advantages of virtual screening over conventional high-throughput
screening, several groups employed virtual screening in combination
with biological assay to identify small molecule inhibitors of various
SENP isoforms [70–73]. Chen et al. [70] reported SENP1 inhibitors
which were identiﬁed by virtual screening for the ﬁrst time. They
docked SPECS library of about 180,000 compounds to SENP1 from the
SENP1–SUMO2–RanGAP1 crystal structure. Thirty-eight compounds
were selected and purchased from the top scoring 100 compounds.
Assessment of bioactivity utilizing ﬂuorescence based assay resulted in
the identiﬁcation of compound 9 (Table 2) with an IC50 of 2.39 μM.
Docking predicted binding mode of compound 9 was further used to
guide the design and synthesis of 2-(4-chlorophenyl)-2-oxoethyl
4-benzamidobenzoate analogs. However, no signiﬁcant improvement
in the activity (best IC50 of 1.08 μM for compound 10) over the parent
compound was observed [70]. Madu et al. [71] virtually screened a
250,000 compound National Cancer Institute library using Glide pro-
gram to obtain 40 compounds for the evaluation of SENP1 and SENP2
inhibitory activities. A gel-based assay that quantiﬁes the maturation
of SUMO-1 and SUMO-2 precursors was used to investigate inhibitory
effects. A luciferase based coupled bioluminescent assay was also used
to determine the inhibition of SENP7 alongwith SENP1 and SENP2. Bio-
assay of initial hits and subsequent analog search revealed compounds
with a novel chemotype (compounds 11 and 12 in Table 2) that do
not covalently modify the catalytic cysteine. The non-competitivescreening method used Reference
lar docking of 180,000 compound library using Glide program. Chen et al. [70]
lar docking of 250,000 compound library using Glide program. Madu et al. [71]
hical virtual screening of ~4 million compound library by shape
ctrostatic similarity search using ROCS and EON program.
lar docking using Glide program prioritized hits for bioassay.
Kumar et al. [72]
lar docking of 100,000 compound library using Dock and
ck program.
Wen et al. [73]
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magnetic resonance (NMR) and quantitative enzyme kinetic experi-
ments. Employing a combination of hierarchical virtual screening and
quantitative FRET based assay, Kumar et al. reported 1,2,5-oxadiazoles
as novel inhibitors of SENP1 and SENP2 [72]. An overview of the virtual
screening protocol used by Kumar et al. is presented in Fig. 3. In summa-
ry, an ~4 M compound library was screened for small molecules that
have similar shape and electrostatic properties with the conjugate of
SUMO-1 C-terminal residues and substrate lysine. Docking and diversity
based selection outlined a set of 49 compounds to be tested for SENP1
and SENP2 inhibitory activities. FRET based assay and subsequent ana-
log search revealed two 1,2,5-oxadiazole core containing scaffolds as a
novel class of SENP1 and SENP2 inhibitors. Identiﬁed inhibitors were
speciﬁc to SENP and no detectable inhibition on other proteases, such
as papain and trypsin, was observed.Wen et al. [73] also utilized hierar-
chical virtual screening to identify a novel cell-permeable inhibitor of
SENP1. They docked about 100,000 drug-like compounds from SPECS
database in a stepwise manner using DOCK and AutoDock program.Shape based 
Electrostatic 
matchi
Dockin
Screening library 
(~4M Compounds) 
FRET base
SENP1 IC50 = 9.7 µM
SENP2 IC50 = 5.9 µM
13
Cherr
Pickin
Fig. 3. An outline of the discovery of 1,2,5-oxadiazoles as novel inhibitors oCherry picking from the top scoring 500 compounds resulted in the
selection of 117 compounds for purchase and evaluation of SENP1
inhibitory activity using a SUMO-CHOP reporter assay [67]. The most
potent compound (compound 15 in Table 2) displayed an IC50 of
1.29 μM for SENP1. Compound 15 was also re-evaluated using in vitro
gel-based SENP activity assay to conﬁrm the inhibitory activity that re-
vealed the inhibition SENP1-mediated cleavage of ΔRanGAP1-SUMO-2.
Further biological assay revealed that compound 15 is a relatively
speciﬁc SENP inhibitor and had little or no effect on the activity of pro-
teasome and other cysteine proteases such as cathepsin B and cathepsin
D. Molecular docking was employed to propose a mechanism of inhibi-
tion that showed that compound 15 binds in a tunnel preventing the
binding of SUMO-1 to SENP1. Computational approaches have been
also used indirectly to facilitate SENP inhibitor discovery efforts from
various groups. Adopting molecular dynamics simulation and quantum
mechanics/molecular mechanics calculations, Shi et al. [76] deciphered
the catalytic mechanism of SENP desumoylation. They identiﬁed critical
residues in SENP1 that might be useful in its inhibitor discovery. Inmatching
potential
ng
g
Query peptide fragment 
1000 compounds
selected
500 compounds
selected
200 compounds
selected
49 compounds
selected
d assay
SENP1 IC50 = >30 µM
SENP2 IC50 = 3.7 µM
14
y
g
f SENP1 and SENP2 utilizing a hierarchical virtual screening approach.
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protein–protein interaction as a viable alternative strategy to target the
enzymatic site [77].
6. Concluding remarks
As discussed in this review, increasing evidence suggests the role of
various SENP isoforms in the development of a number of diseases,
especially prostate cancer. Several studies indicated that inhibition of
SENPs might be a good approach to combat various cancers. In recent
years, considerable progress has been made towards the identiﬁcation
of small molecule inhibitors of various SENP isoforms. However, most
of the developed inhibitors are only suitable as probe molecules to
study the biological mechanism of various SENPs. The therapeutic
potential of most of the presently identiﬁed inhibitors is limited, as
they possess reactive chemical functionalities to facilitate covalent
binding with the active site cysteine. Moreover, none of the identiﬁed
chemical classes is isoform speciﬁc. Similar biological mechanisms,
structural features and chemistry behind the peptide cleavage make it
difﬁcult to identify isoform selective SENP inhibitors. Computational
approaches like molecular docking have been successfully employed
in recent years to identify chemical scaffolds that are much more
amenable for chemical optimization needed for lead development.
However, manymore drug-like chemical scaffolds need to be identiﬁed
along with their structural description of binding to exploit the
therapeutic potential of SENP inhibitors.
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